Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMWH vs Aspirin in Thrombophilia with Recurrent Pregnancy Loss
NCT02986594Phase 4Unknown
- Sponsor
- Shanghai First Maternal and Infant Health Hospital
- Start
- Nov 2016
- Primary completion
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of nadroparin in thrombophilia and recurrent pregnancy loss (RPL) (3 arms), sponsored by Shanghai First Maternal and Infant Health Hospital. Primary endpoint: D-Dimer at 3 years. Status: unknown.
02
Drugs
nadroparin
03
Conditions
thrombophiliarecurrent pregnancy loss (RPL)
Beyond the preview
Go deeper on NCT02986594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02986594.